Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

Vanita R. Aroda(Brigham and Women's Hospital), Ildiko Lingvay(Southwestern Medical Center), Vincent Woo, Rajendra Mehta, Andrew Ahmann(Oregon Health & Science University), Melanie J. Davies(University of Leicester), Esteban Jódar(Universidad Europea de Madrid), Francis C. C. Chow(Chinese University of Hong Kong), Bertrand Cariou(Institut du Thorax)
Diabetes & Metabolism
January 3, 2019
10.1016/j.diabet.2018.12.001
Cited by 281

Related Papers

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2018|3.5k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k